Related Experiment Videos
[Elderly cases of hematological malignancies with second malignancies]
1Department of Hematology, Showa University School of Medicine.
Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
|September 1, 1993
Summary
Elderly patients with hematological malignancies have a significantly higher risk of developing second cancers. Alkylating agent treatment for initial hematologic cancers increases this risk, particularly in older individuals.
Area of Science:
- Hematology
- Oncology
- Geriatrics
Context:
- An increasing prevalence of elderly patients diagnosed with hematological malignancies has been observed.
- This study investigates the incidence and characteristics of second malignancies in this demographic.
- A comparative analysis was conducted between elderly (≥65 years) and non-elderly patients over a five-year period.
Purpose:
- To determine the rate of second malignancies in elderly patients with hematological malignancies.
- To compare the incidence of second malignancies between elderly and non-elderly patient groups.
- To identify specific hematological malignancy types and treatments associated with increased second cancer risk.
Summary:
- Second malignancies occurred in 9.2% (26/282) of all hematological malignancy cases.
- The incidence was significantly higher in the elderly group (20%) compared to the non-elderly group (3.7%).
- Myelodysplastic syndrome and chronic myelo-proliferative disorders were primary hematological malignancies associated with second cancers, predominantly colon, gastric, and lung carcinomas. Treatment with alkylating agents for the initial hematological malignancy was linked to a higher development of second cancers.
Impact:
- Highlights the elevated risk of secondary cancers in elderly patients with hematological malignancies.
- Underscores the potential role of alkylating agent chemotherapy in second cancer development.
- Informs clinical practice regarding surveillance and management strategies for elderly cancer patients.